Royalty Rate Set In Boston, Cordis Stent Spat

Law360, New York (April 13, 2009, 12:00 AM EDT) -- Resolving all remaining issues in a seven-year dispute over stent patents, a federal judge has ruled that Boston Scientific Corp. must pay a 5.1 percent royalty rate on its sales of products infringing on Cordis Corp.'s patents.

The rate applies to catheters sold alone or as part of a stent delivery system, according to the order entered Thursday by U.S. District Judge Susan Illston in the U.S. District Court for the Northern District of California.

Boston Scientific and Johnson & Johnson's Cordis unit were unable to...
To view the full article, register now.